We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
HALO Rises Nearly 4% on Strong 2025 Preliminary Data and 2026 Guidance
Read MoreHide Full Article
Key Takeaways
HALO rose nearly 4% after releasing preliminary full-year 2025 results that beat expectations.
HALO expects royalty revenues of $1.13B-$1.17B in 2026, topping $1B a year earlier than planned.
Halozyme Therapeutics raised 2026 revenue guidance to $1.71B-$1.81B and EPS view to $7.75-$8.25.
Halozyme Therapeutics’ (HALO - Free Report) shares climbed nearly 4%, following the release of preliminary full-year 2025 results on Jan. 28, which beat expectations. The company also raised its sales and EPS guidance for 2026.
HALO’s top line comprises product sales, royalty payments from Roche (RHHBY - Free Report) for Phesgo, J&J (JNJ - Free Report) for subcutaneous Darzalex and argenx’s Vyvgart Hytrulo, along with revenues under collaborative agreements related to its Enhanze technology with several large pharmaceutical companies.
Several companies use HALO’s Enhanze technology to develop a subcutaneous formulation of their currently marketed drugs. The company has 10 marketed partnered drugs based on this technology, including the subcutaneous formulation of J&J’s Darzalex, Roche’s Phesgo and argenx’s Vyvgart Hytrulo.
Over the past year, shares of Halozyme have rallied 29.1% compared with the industry’s 15.6% growth.
Halozyme announced preliminary revenues for full-year 2025 in the range of $1.39 billion to $1.40 billion, up 36% to 38% year over year. The preliminary number surpassed the company’s previously issued guidance of $1.30 billion to $1.38 billion. The guidance range was also higher than the Zacks Consensus Estimate of $1.35 billion.
Royalty revenues are anticipated in the range of $865 to $870 million, representing year-over-year growth of 51% to 52%.
HALO Raises 2026 Guidance
Halozyme Therapeutics expects total revenues in the range of $1.71 billion to $1.81 billion for 2026, representing growth of 23% to 30% over projected 2025 total revenues. Revenues were earlier projected in the range of $1.43 billion to $1.53 billion.
Royalty revenues are now anticipated in the range of $1.13 billion to $1.17 billion, implying year over year growth of 30% to 35%. Previously, royalty revenues were expected to be $900 million-$940 million. The company expects to reach the milestone of surpassing $1 billion in royalty revenues in 2026, a year ahead of its prior expectations.
Adjusted earnings are now expected in the range of $7.75-$8.25 per share in 2026. Adjusted earnings were earlier projected in the band of $6.50-$7.00 per share. The EPS guidance does not consider the impact of potential future share repurchases.
Halozyme estimates adjusted EBITDA to be between $1.12 billion and $1.20 billion, up from the prior range of $1billion-$1.08 billion.
HALO’s raised adjusted EBITDA and earnings per share guidance included the financial impact of approximately $60 million related to the acquisition of Hypercon and Surf Bio technologies, which were not factored into the company’s earlier 2026 guidance. HALO broadened its technology base in December 2025 through the acquisition of Surf Bio, a biopharmaceutical company known for its innovative, hyperconcentration technology. Together with the prior acquisition of Elektrofi in November 2025, these additions bring innovative hyperconcentration technologies that are protected by intellectual property extending into the mid-2040s.
By the end of 2026, the company expects to have 15 partner programs in development and to sign three or more new drug-delivery licensing agreements.
HALO’s Zacks Rank & Key Pick
Halozyme Therapeutics currently carries a Zacks Rank #3 (Hold).
Over the past 60 days, estimates for Alkermes’ 2026 earnings per share have increased from $1.54 to $1.91. ALKS’ shares have risen 6.3% over the past year.
Alkermes’ earnings beat estimates in three quarters and missed in the remaining quarter, with the average earnings surprise being 4.58%.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
HALO Rises Nearly 4% on Strong 2025 Preliminary Data and 2026 Guidance
Key Takeaways
Halozyme Therapeutics’ (HALO - Free Report) shares climbed nearly 4%, following the release of preliminary full-year 2025 results on Jan. 28, which beat expectations. The company also raised its sales and EPS guidance for 2026.
HALO’s top line comprises product sales, royalty payments from Roche (RHHBY - Free Report) for Phesgo, J&J (JNJ - Free Report) for subcutaneous Darzalex and argenx’s Vyvgart Hytrulo, along with revenues under collaborative agreements related to its Enhanze technology with several large pharmaceutical companies.
Several companies use HALO’s Enhanze technology to develop a subcutaneous formulation of their currently marketed drugs. The company has 10 marketed partnered drugs based on this technology, including the subcutaneous formulation of J&J’s Darzalex, Roche’s Phesgo and argenx’s Vyvgart Hytrulo.
Over the past year, shares of Halozyme have rallied 29.1% compared with the industry’s 15.6% growth.
Image Source: Zacks Investment Research
HALO’s Preliminary 2025 Revenues Beat Expectations
Halozyme announced preliminary revenues for full-year 2025 in the range of $1.39 billion to $1.40 billion, up 36% to 38% year over year. The preliminary number surpassed the company’s previously issued guidance of $1.30 billion to $1.38 billion. The guidance range was also higher than the Zacks Consensus Estimate of $1.35 billion.
Royalty revenues are anticipated in the range of $865 to $870 million, representing year-over-year growth of 51% to 52%.
HALO Raises 2026 Guidance
Halozyme Therapeutics expects total revenues in the range of $1.71 billion to $1.81 billion for 2026, representing growth of 23% to 30% over projected 2025 total revenues. Revenues were earlier projected in the range of $1.43 billion to $1.53 billion.
Royalty revenues are now anticipated in the range of $1.13 billion to $1.17 billion, implying year over year growth of 30% to 35%. Previously, royalty revenues were expected to be $900 million-$940 million. The company expects to reach the milestone of surpassing $1 billion in royalty revenues in 2026, a year ahead of its prior expectations.
Adjusted earnings are now expected in the range of $7.75-$8.25 per share in 2026. Adjusted earnings were earlier projected in the band of $6.50-$7.00 per share. The EPS guidance does not consider the impact of potential future share repurchases.
Halozyme estimates adjusted EBITDA to be between $1.12 billion and $1.20 billion, up from the prior range of $1billion-$1.08 billion.
HALO’s raised adjusted EBITDA and earnings per share guidance included the financial impact of approximately $60 million related to the acquisition of Hypercon and Surf Bio technologies, which were not factored into the company’s earlier 2026 guidance. HALO broadened its technology base in December 2025 through the acquisition of Surf Bio, a biopharmaceutical company known for its innovative, hyperconcentration technology. Together with the prior acquisition of Elektrofi in November 2025, these additions bring innovative hyperconcentration technologies that are protected by intellectual property extending into the mid-2040s.
By the end of 2026, the company expects to have 15 partner programs in development and to sign three or more new drug-delivery licensing agreements.
HALO’s Zacks Rank & Key Pick
Halozyme Therapeutics currently carries a Zacks Rank #3 (Hold).
A better-ranked stock in the biotech sector is Alkermes (ALKS - Free Report) , currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Over the past 60 days, estimates for Alkermes’ 2026 earnings per share have increased from $1.54 to $1.91. ALKS’ shares have risen 6.3% over the past year.
Alkermes’ earnings beat estimates in three quarters and missed in the remaining quarter, with the average earnings surprise being 4.58%.